RDD Blog » PPD

R&D Directions Insider

PPD to be acquired by private investment company

Tuesday, October 4th, 2011

Morningstarâ€™s Lauren Migliore believes that the contract research organization industry has turned a corner, citing a resurgence in new business activity and revenue growth during the past few quarters. She notes that â€œthe second quarter marked the first period since the beginning of the drug-development slowdown that the ...

Posted in CRO | No Comments »

PPD puts skin in the game with Celtic alliance

Friday, October 30th, 2009

The typical CRO/sponsor relationship can be prone to delays as a result of the way trials are set up or misunderstandings between the parties. PPD is looking to avoid such delays by bringing products to market more quickly with its recent agreement to invest $100 million in Celtic Therapeutics Holdings ...

Posted in CRO | No Comments »

Big stage for diabetes hopeful

Friday, August 28th, 2009

Recent regulatory setbacks aside, Takeda Pharmaceutical Co. is plowing full steam ahead on its quest to win approval for the companyâ€™s key type 2 diabetes drug alogliptin, another potential entrant into the suddenly competitive field of DPP-4 inhibitors. The Japanese drug giant said today that it received the â€œall-clearâ€ from FDA ...

Posted in CRO, Uncategorized, clinical trials, diabetes, filed for approval | No Comments »

CROs bear brunt as well, numbers show

Wednesday, July 22nd, 2009

Earnings season is upon us once again and when it comes to the drug industry, itâ€™s not just the big fish in big pharma that are under the microscope these days. The top publicly traded contract research organizations are also dealing with added scrutiny as they try to withstand the ...

Posted in CRO, Uncategorized | No Comments »

©2012 UBM Canon